Zepbound helped adolescents lose substantial weight and improve key health measures in a clinical trial.
Younger patients could open a meaningful new market for Eli Lilly’s obesity franchise.
Eli Lilly keeps widening Zepbound’s addressable market while rivals play catch-up.
Eli Lilly (NYSE:LLY) delivered yet another impressive earnings report last month. The company's third-quarter update showed that its core growth drivers, including Mounjaro for diabetes and Zepbound for weight loss, don't seem anywhere close to running out of steam. The best part is that Eli Lilly is actively looking to tap into new market niches, and some of the company's recent clinical trial results could open another important opportunity. Let's look into it.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Zepbound is currently approved for weight loss for adults aged 18 and older, provided their BMI (Body Mass Index) is at least 30 or at least 27 with a weight-related comorbidity. It isn't indicated for anyone younger than that. But Eli Lilly has been running clinical studies to test whether Zepbound is effective in younger patients. It recently reported results from one of those trials.
The study in question enrolled people aged 12 to 17. Half of them had obesity-related complications, while 75% met the threshold for class 2 or class 3 severe obesity. During the study, participants who received Zepbound lost an average of about 40 pounds, while those receiving a placebo gained an average of 5 pounds after 72 weeks.
Also, BMI decreased by 18.5% in patients who took Zepbound, compared with a 0.5% increase in the placebo group. Further, Zepbound led to improvements in various measures, including LDL cholesterol and triglycerides (which are linked to increased cardiovascular risk), as well as improved quality of life.
Safety data were consistent with what we know about GLP-1 drugs. These results could help support a label expansion for Zepbound in younger patients.
There are about 25.6 million people between 12 and 17 years of age in the U.S. The prevalence of obesity among people aged 2 to 19 has been about 21% in recent years, according to the U.S. Centers for Disease Control and Prevention. Applying that to the 12- to 17-year-old population, we get a potential market of more than five million patients -- a significant opportunity.
And that's only in the U.S. Assuming Eli Lilly can generate about $6,000 in net revenue per patient and the pharmaceutical company reaches 20% penetration in this population, we are talking about an additional annual net revenue of about $6.5 billion.
Note that in the third quarter, Zepbound generated $5.4 billion in revenue, up 49% year over year. Eli Lilly's total revenue grew 39% year over year to $24.4 billion. An additional $6.5 billion in annual sales from Zepbound would therefore be meaningful. Of course, there are important caveats to consider.
For one, it will take time for Eli Lilly to ramp up Zepbound sales in this niche. Also, Eli Lilly will face competition in this market. The company's biggest challenger, Novo Nordisk (NYSE:NVO), has earned approval for its famous GLP-1 drug, Wegovy, in this patient population.
Third, Eli Lilly's net realized prices might decline as more weight loss drugs enter the market. Even with these caveats, this opportunity looks potentially highly lucrative for Eli Lilly. The company has proven that Zepbound is more effective than Wegovy. And given the benefits Zepbound demonstrated in adolescents beyond weight loss, it should attract a significant share of that market, even with increased competition. However, does this make Eli Lilly stock a buy?
The potential label expansion for Zepbound in adolescents appears attractive, and it once again highlights Eli Lilly's strength in one of its core therapeutic areas. Eli Lilly is also running clinical trials for Zepbound in patients between six and 11 years of age, which could add more than five million patients to its addressable market, provided the medicine proves effective in this study.
And we haven't even mentioned the several other clinical trial candidates the company has in weight loss or, for that matter, the deep pipeline it has built in other therapeutic areas, such as oncology. So, Eli Lilly's prospects look attractive. The stock has outperformed broader equities this year -- and since the turn of the decade, for that matter -- but there may be plenty of upside left.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.